ANKRD26 Overexpression Triggers Megakaryocyte Apoptosis via JUNB-p21 Pathway

Inherited platelet disorders present a significant diagnostic challenge for clinicians, as these lifelong cytopenias are frequently misidentified as chronic immune thrombocytopenia [1, 2]. Among these conditions, ANKRD26-related thrombocytopenia 2 (THC2) is clinically critical due to its established association with a predisposition for myelodysplastic syndrome and acute myeloid leukemia [3, 4, 5]. Although the World Health Organization recognizes these germline predispositions in its classification of myeloid neoplasms, the mechanisms by which these mutations impair megakaryopoiesis, the process of platelet production from precursor cells, have remained largely theoretical [6, 7]. Current management typically relies on supportive care or thrombopoietin receptor agonists, which are agents that stimulate platelet production, yet the lack of targeted therapies reflects a gap in understanding how these genetic variants drive bone marrow failure [8, 9, 10]. A comprehensive study of four independent patients now provides a detailed molecular portrait of the cellular defects underlying this condition, identifying a consistent expansion of megakaryocyte progenitors and a marked reduction in polyploid megakaryocytes, which are mature cells containing multiple sets of chromosomes, driven by the JUNB-p21 signaling pathway [11].